WS
NBSE

Wedbush Securities’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Wedbush Securities’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-338
Closed -$12K – 959
2018
Q4 		$12K Buy
338
+150
+80% +$10.9K ﹤0.01% 822
2018
Q3 		$14K Hold
188
– – ﹤0.01% 892
2018
Q2 		$15K Hold
188
– – ﹤0.01% 871
2018
Q1 		$16K Sell
188
-1,469
-89% -$218K ﹤0.01% 810
2017
Q4 		$1.23M Buy
1,657
+577
+53% +$223K 0.15% 151
2017
Q3 		$311K Buy
+1,080
New +$295K 0.04% 534

Other funds holding NBSE

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MIG
Mariner Investment Group Harrison, New York $346M AUM 25.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SSB
Sandy Spring Bank Olney, Maryland $2.38B AUM 8.14% 1-Year Est. Return
WAM
Wealthspire Advisors (Maryland) Potomac, Maryland $2.84B AUM 10.91% 1-Year Est. Return

Wedbush Securities's NBSE Position: Q1 2019 in Review

Wedbush Securities sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q1 2019, closing a stake of 338 shares — an estimated $12K sold.

Wedbush Securities first reported a position in NBSE in Q3 2017 and held it in 6 quarters. The position peaked at $1.23M in Q4 2017. 15 funds tracked by Wall St. Rank hold NBSE as of Q1 2019.

  • Wedbush Securities reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • Wedbush Securities sold 338 NeuBase Therapeutics, Inc. Common Stock shares in Q1 2019, an estimated $12K.
  • Wedbush Securities first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q3 2017 and held it in 6 quarters.
  • Wedbush Securities's NeuBase Therapeutics, Inc. Common Stock position peaked at $1.23M in Q4 2017.
  • 15 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q1 2019.

Based on Wedbush Securities's 13F filing for Q1 2019, filed 17 Apr 2019.